Study of experimental drug for Alzheimer's disease
Part of Brain & nervous system, Mental health clinical trials.
This study tests an experimental drug called LY4405094 in healthy people and in people with Alzheimer's disease. It aims to see if the drug is safe and how the body handles it, which could lead to new treatments for Alzheimer's.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be enrolled in a separate screening study before joining this one.
- You must not have allergies to the study drug or related compounds.
- You must not have known allergic reactions to adhesives or hydrogels, or a family history of adhesive skin allergies.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests several new experimental medications that target amyloid plaques, the protein clumps linked to Alzheimer's disease. It aims to find out if these treatments are safe and well-tolerated in people with early-stage Alzheimer's and in healthy volunteers.
This study tests an investigational medication in healthy volunteers and people with Alzheimer's disease. It aims to understand how the drug works and its safety.
This trial tests a new medicine called LY4006895 in two groups: healthy volunteers and people with early symptomatic Alzheimer's disease. It aims to see how the drug works in the body and if it might help memory and thinking.
This study tests an experimental drug called LY3439539 in people with early-stage Alzheimer's disease. The drug is designed to target protein changes in the brain that may slow memory loss and cognitive decline.
This study tests an experimental drug (LY3954068) for people with early Alzheimer's disease. It aims to see if the drug is safe and may slow memory loss. You'll need a PET scan to measure tau protein in the brain and have a study partner who can help attend appointments.
This trial tests an experimental drug, ARO-MAPT-SC, which may slow the progression of early Alzheimer's disease by targeting a protein involved in the disease. It is given as an injection under the skin and is being studied in healthy people and those with early Alzheimer's.
Hear when a new Amyloid trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.